Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260768 | 0.88 | GPR35 (0.67) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| Benzene SCHEMBL27490159 | 0.84 | GPR35 (0.61) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL9719276 | 0.80 | GPR35 (0.57) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL5200622 | 0.80 | ALDH1A1 (0.66) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL29720617 | 0.80 | ALDH1A1 (0.66) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL11133854 | 0.79 | CYP1A2 (0.67) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL9699609 | 0.78 | GPR35 (0.55) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL15285954 | 0.78 | GPR35 (0.55) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL349045 | 0.78 | GPR35 (0.55) | GPR35CYP1A2TSHRCYP3A4KDM4E | |
| SCHEMBL349463 | 0.78 | GPR35 (0.55) | GPR35CYP1A2TSHRCYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| WO-2018011201-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
| US-9580379-B2 | Xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | BAYLOR COLLEGE OF MEDICINE | 2015-12-10 | — | — | US | disclosed |
| US-7956165-B2 | Ligand and coordinating moiety for isolating preferential macromolecules in solution | AFFISINK BIOTECHNOLOGY LTD. (IL) | 2011-06-07 | — | — | US | disclosed |
| US-20080108053-A1 | Compositions and methods for purifying and crystallizing molecules of interest | AFFISINK BIOTECHNOLOGY LTD. (IL) | 2008-05-08 | — | — | US | disclosed |
| US-5500060-A | IMPROVED SAFETY RELATED TO UNWANTED IGNITION, NITRAMINE COMPOUNDS, AROMATIC NITRO COMPOUNDS | ROYAL ORDNANCE PLC (GB) | 1996-03-19 | — | — | US | disclosed |
| US-5138098-A | Catalytic actlation using complexing agent | AMOCO CORPORATION (US) | 1992-08-11 | — | — | US | disclosed |
| US-4051187-A | CARBON CATALYST WITH SYNERGISTIC QUANTITIES OF THODIUM, TRICHLORIDE OR RHODIUM TRIBROMIDE | OXAMINE, INC. (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353471-A1 | XANTHINE OXIDASE INHIBITORS AND METHODS OF USE | XDH, PNPO, AOX1 | GPR35 3170/4885CYP1A2 104/4885TSHR 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.